175 related articles for article (PubMed ID: 21083942)
1. Effects of GnRH agonist treatment on steroidogenesis and folliculogenesis in the ovary of cyclic mice.
Singh P; Krishna A
J Ovarian Res; 2010 Nov; 3():26. PubMed ID: 21083942
[TBL] [Abstract][Full Text] [Related]
2. Luteal granulosa cells from natural cycles are more capable of maintaining their viability, steroidogenic activity and LH receptor expression than those of stimulated IVF cycles.
Bildik G; Akin N; Seyhan A; Esmaeilian Y; Yakin K; Keles I; Balaban B; Ata B; Urman B; Oktem O
Hum Reprod; 2019 Feb; 34(2):345-355. PubMed ID: 30520979
[TBL] [Abstract][Full Text] [Related]
3. [The effects of GnRH agonist on steroidogenesis in the rat ovary].
Yago N
Nihon Naibunpi Gakkai Zasshi; 1994 Aug; 70(6):543-54. PubMed ID: 7958104
[TBL] [Abstract][Full Text] [Related]
4. Direct effects of RFRP-1, a mammalian GnIH ortholog, on ovarian activities of the cyclic mouse.
Dave A; Krishna A; Tsutsui K
Gen Comp Endocrinol; 2017 Oct; 252():193-199. PubMed ID: 28658602
[TBL] [Abstract][Full Text] [Related]
5. Direct inhibitory effect of gonadotropin-releasing hormone upon luteal luteinizing hormone receptor and steroidogenesis in hypophysectomized rats.
Jones PB; Hsueh AJ
Endocrinology; 1980 Dec; 107(6):1930-6. PubMed ID: 6253282
[TBL] [Abstract][Full Text] [Related]
6. Antigonadotropic actions of GnRH agonist on ovarian cells in vivo and in vitro.
Maruo T; Otani T; Mochizuki M
J Steroid Biochem; 1985 Nov; 23(5B):765-70. PubMed ID: 3001418
[TBL] [Abstract][Full Text] [Related]
7. Effect of mifepristone (RU486) on the pituitary response to gonadotrophin releasing hormone in women.
Kazem R; Messinis LE; Fowler P; Groome NP; Knight PG; Templeton AA
Hum Reprod; 1996 Dec; 11(12):2585-90. PubMed ID: 9021355
[TBL] [Abstract][Full Text] [Related]
8. Effect of gonadotrophin-releasing hormone agonist-induced suppression of LH and FSH on follicle growth and corpus luteum function in the ewe.
McNeilly AS; Fraser HM
J Endocrinol; 1987 Nov; 115(2):273-82. PubMed ID: 3125300
[TBL] [Abstract][Full Text] [Related]
9. GnRH action on luteal steroidogenesis during pregnancy.
Sridaran R; Lee MA; Haynes L; Srivastava RK; Ghose M; Sridaran G; Smith CJ
Steroids; 1999 Sep; 64(9):618-23. PubMed ID: 10503718
[TBL] [Abstract][Full Text] [Related]
10. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
[TBL] [Abstract][Full Text] [Related]
11. Effects of gonadotropin-releasing hormone agonist and antagonist on ovarian activity in a mouse model for polycystic ovary.
Singh P; Srivastava RK; Krishna A
J Steroid Biochem Mol Biol; 2016 Oct; 163():35-44. PubMed ID: 27036999
[TBL] [Abstract][Full Text] [Related]
12. Follicular development, steroidogenesis and gonadotrophin secretion in response to long-term treatment with a gonadotrophin-releasing hormone agonist in the rat.
Srivastava RK; Krishna A; Sridaran R
J Endocrinol; 1995 Aug; 146(2):349-57. PubMed ID: 7561648
[TBL] [Abstract][Full Text] [Related]
13. Both in vivo FSH depletion and follicular exposure to Gonadotrophin-releasing hormone analogues in vitro are not effective to prevent follicular depletion during chemotherapy in mice.
Horicks F; Van Den Steen G; Gervy C; Clarke HJ; Demeestere I
Mol Hum Reprod; 2018 Apr; 24(4):221-232. PubMed ID: 29438534
[TBL] [Abstract][Full Text] [Related]
14. Gonadotropin-releasing hormone analogue binds to luteal cells and inhibits progesterone production.
Clayton RN; Harwood JP; Catt KJ
Nature; 1979 Nov; 282(5734):90-2. PubMed ID: 228197
[TBL] [Abstract][Full Text] [Related]
15. Administration of a gonadotropin-releasing hormone agonist affects corpus luteum vascular stability and development and induces luteal apoptosis in a rat model of ovarian hyperstimulation syndrome.
Scotti L; Irusta G; Abramovich D; Tesone M; Parborell F
Mol Cell Endocrinol; 2011 Mar; 335(2):116-25. PubMed ID: 21238536
[TBL] [Abstract][Full Text] [Related]
16. Human ovarian steroid secretion in vivo: effects of GnRH agonist versus antagonist (cetrorelix).
Garcia-Velasco JA; Isaza V; Vidal C; Landazábal A; Remohí J; Simón C; Pellicer A
Hum Reprod; 2001 Dec; 16(12):2533-9. PubMed ID: 11726570
[TBL] [Abstract][Full Text] [Related]
17. FSH Stimulation promotes progesterone synthesis and output from human granulosa cells without luteinization.
Oktem O; Akin N; Bildik G; Yakin K; Alper E; Balaban B; Urman B
Hum Reprod; 2017 Mar; 32(3):643-652. PubMed ID: 28158500
[TBL] [Abstract][Full Text] [Related]
18. Gonadotropin-releasing hormone and its agonist inhibit testicular luteinizing hormone receptor and steroidogenesis in immature and adult hypophysectomized rats.
Bambino TH; Schreiber JR; Hsueh AJ
Endocrinology; 1980 Oct; 107(4):908-17. PubMed ID: 6250797
[TBL] [Abstract][Full Text] [Related]
19. Noradrenaline modulates the presence of gonadotropin-releasing hormone in ovary. The importance of its interrelation on the ovarian steroidogenesis and apoptosis on dioestrus II in rat.
Bronzi CD; Orozco AS; Rodriguez D; Rastrilla AM; Sosa ZY; Casais M
J Steroid Biochem Mol Biol; 2015 Nov; 154():39-46. PubMed ID: 26144997
[TBL] [Abstract][Full Text] [Related]
20. Modulation of steroidogenesis by vitamin D3 in granulosa cells of the mouse model of polycystic ovarian syndrome.
Bakhshalizadeh S; Amidi F; Alleyassin A; Soleimani M; Shirazi R; Shabani Nashtaei M
Syst Biol Reprod Med; 2017 Jun; 63(3):150-161. PubMed ID: 28345956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
